Allantoin

What is it?

Allantoin is a naturally occurring nitrogenous compound found in comfrey root (Symphytum officinale), sugar beet, wheat sprouts, and chamomile, and is also a metabolic byproduct of uric acid oxidation in most mammals. In modern skincare, it is produced synthetically for consistency and purity. The U.S. FDA officially recognizes allantoin as a Category I skin protectant at concentrations of 0.5%–2%, making it one of very few cosmetic ingredients with both an established safety profile and formal regulatory endorsement for protective claims. Its use in wound healing dates back centuries — comfrey poultices were applied to wounds and bone fractures in medieval European medicine, long before the active compound was identified. Allantoin's mechanism of action is multifaceted and unusually gentle. It stimulates cell proliferation in the stratum germinativum (basal layer), accelerating the turnover of damaged or aged keratinocytes without the irritation associated with chemical exfoliants like AHAs or retinoids. Simultaneously, it acts as a keratolytic agent, softening the intercellular matrix of the stratum corneum to promote gentle desquamation of dead surface cells. This dual action — proliferative from below, keratolytic from above — creates a self-renewing surface without disrupting the skin barrier. Additionally, allantoin is a modest humectant, capable of binding water in the stratum corneum and improving skin hydration. What makes allantoin exceptional among active ingredients is its anti-irritant and soothing profile. It suppresses irritation from other topical actives, reduces transepidermal water loss (TEWL) at compromised sites, and has demonstrated wound-healing acceleration in multiple in vivo models. This rare combination of cell-turnover promotion without irritation makes allantoin one of the most universally tolerated active ingredients in dermatology — suitable for neonatal skin, post-procedure care, and the most reactive skin types.

How It Works

1. 1

   Stimulates Basal Cell Proliferation

   Allantoin promotes mitotic activity in the stratum germinativum, accelerating the production of fresh keratinocytes that replace damaged or aged surface cells.

2. 2

   Keratolytic Desquamation

   It softens the intercellular cement of the stratum corneum, enabling gentle shedding of dead surface cells without the irritation of chemical exfoliants.

3. 3

   Moisture Binding and Barrier Support

   As a humectant, allantoin binds water in the upper epidermis, reducing transepidermal water loss and supporting the skin barrier that PDRN's deeper repair depends on.

4. 4

   Anti-Irritant Buffering

   Allantoin suppresses inflammatory responses to topical actives and environmental stressors, creating a calmer environment for PDRN's A2A receptor-mediated regeneration to proceed without interference.

Role in PDRN

In PDRN-based skincare protocols, allantoin serves as the gentle surface-repair partner that complements PDRN's deep cellular regeneration. While PDRN activates fibroblast proliferation and collagen synthesis through the adenosine A2A receptor pathway in the dermis, allantoin works at the epidermal level — stimulating keratinocyte turnover in the basal layer and promoting soft desquamation of the stratum corneum. The result is a full-thickness renewal strategy: PDRN rebuilds from within while allantoin resurfaces from above, and neither component causes irritation. This combination is especially valuable in post-procedure and sensitive skin contexts, where the skin barrier is compromised and irritation tolerance is at its lowest. Allantoin's anti-irritant properties effectively buffer any transient sensitivity from active ingredient penetration, while its wound-healing acceleration works in concert with PDRN's tissue-repair signaling. Several Korean PDRN creams include allantoin as a co-active ingredient precisely because it allows the formulation to deliver regenerative actives into freshly treated or reactive skin without triggering inflammation or barrier disruption.

Clinical Data

Allantoin has a long-established safety and efficacy record, forming the basis of its FDA Category I skin protectant classification. In vivo wound-healing studies have demonstrated that allantoin at 1%–2% accelerates epithelial migration and fibroblast activation at wound margins, reducing healing time in superficial wounds and post-procedure recovery models. A comparative study on post-laser skin recovery found that allantoin-containing formulations reduced erythema duration and TEWL more effectively than placebo vehicles. Cell proliferation assays confirm that allantoin stimulates mitosis in the basal layer of the epidermis without cytotoxicity, distinguishing it from harsher keratolytic agents. While large-scale randomized controlled trials specifically pairing allantoin with PDRN are not yet published, the complementary mechanisms — epidermal turnover via allantoin plus dermal regeneration via PDRN — are well-supported by the independent evidence bases for each ingredient.

Product Formats in the Wild

Common ways this ingredient is delivered in clinical and consumer products.